-
Something wrong with this record ?
Viridans group streptococci bloodstream infections in neutropenic adult patients with hematologic malignancy: Single center experience
J. Radocha, P. Paterová, A. Zavřelová, B. Víšek, F. Gabalec, H. Žemličková, P. Žák,
Language English Country United States
Document type Journal Article
Grant support
NV17-28539A
MZ0
CEP Register
- MeSH
- Anti-Bacterial Agents administration & dosage MeSH
- Bacteremia drug therapy microbiology MeSH
- Adult MeSH
- Hematologic Neoplasms drug therapy microbiology MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Streptococcal Infections drug therapy microbiology MeSH
- Viridans Streptococci classification drug effects genetics isolation & purification MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
Viridans group streptococci bloodstream infections (VGS BSI) remain a significant cause of mortality and morbidity in patients with severe neutropenia. The goal of our study was to evaluate clinical course and microbiological susceptibility of VGS BSI at our center. Retrospective analysis of all microbiologically documented bloodstream infections caused by VGS during the 9-year time period (from January 2006 until December 2014) was carried out. Only patients with severe neutropenia (< 500/μL) were included in the study. Clinical outcome and microbiological susceptibility pattern of isolates were recorded. Fifty-one individual patients with episode of VGS BSI were identified. The most frequent agent was Streptococcus mitis (23/51 cases, 45.1%). 88.2% (45/51) of patients were on recommended ciprofloxacin prophylaxis. 20/51 (39.2%) of patients suffered from mucositis at the time of diagnosis (10 patients had oral mucositis, 2 patients had bowel mucositis, and 8 patients both). Twenty-six patients (51.0%) had clinically relevant lung damage caused by VGS BSI (i.e., acute lung injury or acute respiratory distress syndrome). Twenty-four (47.0%) patients presented with bilateral lung infiltrated upon chest imaging, and two (4.0%) patients had unilateral lung infiltrates. Three patients (5.9%) died due to VGS BSI until day 28 of observation. No difference in signs of shock syndrome was observed in the patients during transplantation procedures compared to patients without transplantation as well as in a group received previous high-dose chemotherapy with cytosinarabinoside or in patients with mucositis. Only 3/51 of isolates (5.9%) were resistant to penicillin. All isolates were susceptible to empirical treatment. While the penicillin resistance of VGS remains low in middle Europe, initial antibiotic therapy of febrile neutropenia are still effective in most cases. The mortality and complication rates of VGS BSI were comparable to other studies, and no specific risk factor of shock presence could be identified.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18028582
- 003
- CZ-PrNML
- 005
- 20190304084101.0
- 007
- ta
- 008
- 180816s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12223-017-0542-7 $2 doi
- 035 __
- $a (PubMed)28776170
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Radocha, Jakub $7 xx0233189 $u 4th Department of Internal Medicine - Haematology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic. jakub.radocha@centrum.cz.
- 245 10
- $a Viridans group streptococci bloodstream infections in neutropenic adult patients with hematologic malignancy: Single center experience / $c J. Radocha, P. Paterová, A. Zavřelová, B. Víšek, F. Gabalec, H. Žemličková, P. Žák,
- 520 9_
- $a Viridans group streptococci bloodstream infections (VGS BSI) remain a significant cause of mortality and morbidity in patients with severe neutropenia. The goal of our study was to evaluate clinical course and microbiological susceptibility of VGS BSI at our center. Retrospective analysis of all microbiologically documented bloodstream infections caused by VGS during the 9-year time period (from January 2006 until December 2014) was carried out. Only patients with severe neutropenia (< 500/μL) were included in the study. Clinical outcome and microbiological susceptibility pattern of isolates were recorded. Fifty-one individual patients with episode of VGS BSI were identified. The most frequent agent was Streptococcus mitis (23/51 cases, 45.1%). 88.2% (45/51) of patients were on recommended ciprofloxacin prophylaxis. 20/51 (39.2%) of patients suffered from mucositis at the time of diagnosis (10 patients had oral mucositis, 2 patients had bowel mucositis, and 8 patients both). Twenty-six patients (51.0%) had clinically relevant lung damage caused by VGS BSI (i.e., acute lung injury or acute respiratory distress syndrome). Twenty-four (47.0%) patients presented with bilateral lung infiltrated upon chest imaging, and two (4.0%) patients had unilateral lung infiltrates. Three patients (5.9%) died due to VGS BSI until day 28 of observation. No difference in signs of shock syndrome was observed in the patients during transplantation procedures compared to patients without transplantation as well as in a group received previous high-dose chemotherapy with cytosinarabinoside or in patients with mucositis. Only 3/51 of isolates (5.9%) were resistant to penicillin. All isolates were susceptible to empirical treatment. While the penicillin resistance of VGS remains low in middle Europe, initial antibiotic therapy of febrile neutropenia are still effective in most cases. The mortality and complication rates of VGS BSI were comparable to other studies, and no specific risk factor of shock presence could be identified.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antibakteriální látky $x aplikace a dávkování $7 D000900
- 650 _2
- $a bakteriemie $x farmakoterapie $x mikrobiologie $7 D016470
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a hematologické nádory $x farmakoterapie $x mikrobiologie $7 D019337
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a streptokokové infekce $x farmakoterapie $x mikrobiologie $7 D013290
- 650 _2
- $a viridující streptokoky $x klasifikace $x účinky léků $x genetika $x izolace a purifikace $7 D034363
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Paterová, P $u Institute of Clinical Microbiology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic.
- 700 1_
- $a Zavřelová, A $u 4th Department of Internal Medicine - Haematology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic.
- 700 1_
- $a Víšek, B $u 4th Department of Internal Medicine - Haematology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic.
- 700 1_
- $a Gabalec, F $u 4th Department of Internal Medicine - Haematology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic.
- 700 1_
- $a Žemličková, H $u Institute of Clinical Microbiology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic.
- 700 1_
- $a Žák, P $u 4th Department of Internal Medicine - Haematology, University Hospital Hradec Králové, Charles University, Sokolská 581, 50005, Hradec Králové, Czech Republic.
- 773 0_
- $w MED00011005 $t Folia microbiologica $x 1874-9356 $g Roč. 63, č. 2 (2018), s. 141-146
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28776170 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180816 $b ABA008
- 991 __
- $a 20190304084412 $b ABA008
- 999 __
- $a ok $b bmc $g 1326576 $s 1025537
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 63 $c 2 $d 141-146 $e 20170803 $i 1874-9356 $m Folia microbiologica $n Folia microbiol. (Prague) $x MED00011005
- GRA __
- $a NV17-28539A $p MZ0
- LZP __
- $a Pubmed-20180816